Ahmed Gawish
@gawish.bsky.social
Radiation oncologist/ Ass.Professor/ University Marburg 🇩🇪/ #Radonc
What a start , @mguckenberger.bsky.social with an emotional and inspiring talk at the opening Ceremony, Pascal Uffer delivered more than a talk ; if cancer were a start up. #ESTRO25 #radonc #radiotherapy
May 2, 2025 at 7:32 PM
What a start , @mguckenberger.bsky.social with an emotional and inspiring talk at the opening Ceremony, Pascal Uffer delivered more than a talk ; if cancer were a start up. #ESTRO25 #radonc #radiotherapy
In the KEYNOTE-689 trial, neoadjuvant pembrolizumab delivered a game-changing:
✅ Event-Free Survival (EFS) Hazard Ratio: 0.73 (95% CI: 0.58–0.92)
✅ Median EFS: 51.8 months vs. 30.4 months
No clear benefit seen in the hypopharynx subgroup
#HNSCC #Radonc #Immunotherapy #CancerResearch
✅ Event-Free Survival (EFS) Hazard Ratio: 0.73 (95% CI: 0.58–0.92)
✅ Median EFS: 51.8 months vs. 30.4 months
No clear benefit seen in the hypopharynx subgroup
#HNSCC #Radonc #Immunotherapy #CancerResearch
April 28, 2025 at 3:47 AM
In the KEYNOTE-689 trial, neoadjuvant pembrolizumab delivered a game-changing:
✅ Event-Free Survival (EFS) Hazard Ratio: 0.73 (95% CI: 0.58–0.92)
✅ Median EFS: 51.8 months vs. 30.4 months
No clear benefit seen in the hypopharynx subgroup
#HNSCC #Radonc #Immunotherapy #CancerResearch
✅ Event-Free Survival (EFS) Hazard Ratio: 0.73 (95% CI: 0.58–0.92)
✅ Median EFS: 51.8 months vs. 30.4 months
No clear benefit seen in the hypopharynx subgroup
#HNSCC #Radonc #Immunotherapy #CancerResearch
The RACE-GB trial results are here! FIRST randomized controlled trial investigating radiotherapy (RT) in gallbladder cancer.
In a cohort of 135 patients the addition of RT after 4 cycles of chemotherapy (compared to observation) extended overall survival (OS) from 4 months to 10 months.@RadOnc
In a cohort of 135 patients the addition of RT after 4 cycles of chemotherapy (compared to observation) extended overall survival (OS) from 4 months to 10 months.@RadOnc
December 14, 2024 at 4:31 PM
The RACE-GB trial results are here! FIRST randomized controlled trial investigating radiotherapy (RT) in gallbladder cancer.
In a cohort of 135 patients the addition of RT after 4 cycles of chemotherapy (compared to observation) extended overall survival (OS) from 4 months to 10 months.@RadOnc
In a cohort of 135 patients the addition of RT after 4 cycles of chemotherapy (compared to observation) extended overall survival (OS) from 4 months to 10 months.@RadOnc